Results 21 to 30 of about 885,175 (334)

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Clinical Cancer Research, 2020
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to ...
M. Middleton, C. McAlpine, V. Woodcock, P. Corrie, J. Infante, N. Steven, T. Evans, A. Anthoney, A. Shoushtari, O. Hamid, Avinash Gupta, Antonella Vardeu, E. Leach, Revashnee Naidoo, S. Stanhope, S. Lewis, J. Hurst, I. O'kelly, M. Sznol   +18 more
semanticscholar   +1 more source

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Nature Communications, 2021
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 ...
L. Ny, H. Jespersen, J. Karlsson, Samuel Alsén, S. Filges, Charlotta All-Eriksson, B. Andersson, A. Carneiro, H. Helgadottir, M. Levin, I. Ljuslinder, R. Olofsson Bagge, V. Sah, U. Stierner, A. Ståhlberg, G. Ullenhag, L. Nilsson, J. Nilsson   +17 more
semanticscholar   +1 more source

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Journal of Immunological Research, 2020
Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune‐compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by ...
M. Ralli, A. Botticelli, I. C. Visconti, D. Angeletti, M. Fiore, P. Marchetti, A. Lambiase, M. de Vincentiis, A. Greco   +8 more
semanticscholar   +1 more source

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

New England Journal of Medicine, 2019
BACKGROUND Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.
C. Robert, J. Grob, D. Stroyakovskiy, B. Karaszewska, A. Hauschild, E. Levchenko, V. Chiarion Sileni, J. Schachter, C. Garbe, I. Bondarenko, H. Gogas, M. Mandalà, J. Haanen, C. Lebbé, A. Mackiewicz, P. Rutkowski, P. Nathan, A. Ribas, M. Davies, K. Flaherty, P. Burgess, M. Tan, E. Gasal, M. Voi, D. Schadendorf, G. Long   +25 more
semanticscholar   +1 more source

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes

Medical Sciences, 2022
Molecular and histopathological analysis of melanoma subtypes has revealed distinct epidemiological, genetic, and clinical features. However, immunotherapy for advanced metastatic melanoma patients does not differ based on subtype.
Charlotte Andrieu, Niamh McNamee, Anne-Marie Larkin, Alanna Maguire, Roopika Menon, Judith Mueller-Eisert, Noel Horgan, Susan Kennedy, Giuseppe Gullo, John Crown, Naomi Walsh   +10 more
doaj   +1 more source

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

Nature Medicine, 2012
Tumor-derived exosomes are emerging mediators of tumorigenesis. We explored the function of melanoma-derived exosomes in the formation of primary tumors and metastases in mice and human subjects.
H. Peinado, M. Alečković, S. Lavotshkin, Irina R Matei, B. Costa-Silva, G. Moreno-Bueno, M. Hergueta-Redondo, Caitlin Williams, G. García‐Santos, Cyrus M. Ghajar, Ayuko Nitadori-Hoshino, Caitlin E. Hoffman, K. Badal, B. Garcia, M. Callahan, Jianda Yuan, V. Martins, J. Skog, R. Kaplan, M. Brady, J. Wolchok, P. Chapman, Yibin Kang, J. Bromberg, D. Lyden   +24 more
semanticscholar   +1 more source

IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA

Медицинский совет, 2016
Metastatic melanoma remains a refractory disease. Great progress in therapy of metastatic melanoma patients has been made in the recent five years. Targeted immunotherapy – a selective effect on lymphocytes signal molecules - became a principally new ...
I. V. SAMOILENKO, G. Y. KHARKEVICH, L. V. DEMIDOV   +2 more
doaj   +1 more source

Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data

BMC Cancer, 2018
Background Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials investigating ...
Qiufei Ma, Mark Shilkrut, Zhongyun Zhao, Minming Li, Nicolas Batty, Beth Barber   +5 more
doaj   +1 more source

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Clinical Cancer Research, 2020
Purpose: Resistance to anti-PD1–based immune checkpoint blockade (ICB) remains a problem for the treatment of metastatic melanoma. Tumor cells as well as host myeloid cells can express the immune checkpoint ligand CD155 to regulate immune cell function ...
A. Lepletier, J. Madore, Jake S. O’Donnell, R. Johnston, Xian-Yang Li, E. McDonald, Elizabeth Ahern, A. Kuchel, M. Eastgate, Sally-Ann Pearson, D. Mallardo, P. Ascierto, D. Massi, B. Merelli, M. Mandalà, J. Wilmott, A. Menzies, Charles Leduc, J. Stagg, Bertrand Routy, G. Long, R. Scolyer, T. Bald, N. Waddell, W. Dougall, M. Teng, M. Smyth   +26 more
semanticscholar   +1 more source

New Insights into the Role of Sphingolipid Metabolism in Melanoma

Cells, 2020
Cutaneous melanoma is a deadly skin cancer whose aggressiveness is directly linked to its metastatic potency. Despite remarkable breakthroughs in term of treatments with the emergence of targeted therapy and immunotherapy, the prognosis for metastatic ...
Lorry Carrié, Mathieu Virazels, Carine Dufau, Anne Montfort, Thierry Levade, Bruno Ségui, Nathalie Andrieu-Abadie   +6 more
doaj   +1 more source